Wall Street’s $10B India hospital bet stirs bill fight

Wall Street-backed investors have poured approximately $10 billion into Indian hospital chains over the past five years, fueling a rapid expansion of healthcare infrastructure in the country. This influx of capital has driven up hospital revenues and valuations, generating significant returns for some investors while raising concerns about rising costs and reduced access to care.

In August, a parliamentary committee expressed alarm over the growing influence of foreign capital in India's private hospital sector, warning of potential abuse and recommending stricter rules for foreign investment, price caps, and the creation of a hospital regulator. The concern echoes debates in other countries, where private capital has been both praised for expanding healthcare capacity and criticized for driving up costs.

Critics argue that private providers, including PE-backed chains, are inflating bills and pushing patients towards high-cost procedures, while operators contend that delayed reimbursements and low reimbursement rates are squeezing operating margins. In the U.S., lawmakers and insurers have long grappled with similar questions as private equity firms have sought to grow healthcare capacity without compromising patient access.

The stark contrast between India's underdeveloped healthcare infrastructure and the soaring demand for specialized services such as cardiac care and cancer treatment has made the country an attractive investment opportunity for global investors. Despite representing only a small fraction of hospital beds, PE-backed operators dominate high-margin specialties, commanding premium prices and commanding significant returns.

India's capital markets have provided a conducive environment for PE firms seeking to cash out through public listings and secondary share sales. Temasek Holdings, for instance, has reportedly generated a remarkable 10-fold return on its 2017 investment in Manipal Health Enterprises, showcasing the potential rewards of the hospital sector for savvy investors.

However, the industry's financial success has also sparked concerns about the affordability of care, with medical inflation running as high as 13% annually. With treatment costs often five to 10 times higher in private hospitals compared to public facilities, particularly in cancer care, cardiac treatment, kidney failure, and maternity services, policymakers are increasingly scrutinizing the balance between expanding healthcare capacity and maintaining affordability.